Cabio Biotech (Wuhan) Co., Ltd. (688089.SS)
CNY 20.17
(-0.93%)
CNY 20.17
(-0.93%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 443.8 Million CNY | 2.78% |
| 2022 | 433.42 Million CNY | 23.44% |
| 2021 | 351.1 Million CNY | 8.55% |
| 2020 | 323.46 Million CNY | 3.82% |
| 2019 | 311.54 Million CNY | 8.89% |
| 2018 | 286.1 Million CNY | 25.18% |
| 2017 | 228.55 Million CNY | 20.42% |
| 2016 | 189.8 Million CNY | 4.77% |
| 2015 | 181.15 Million CNY | -2.88% |
| 2014 | 186.52 Million CNY | -6.76% |
| 2013 | 200.05 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 126.31 Million CNY | -12.17% |
| 2024 Q2 | 143.81 Million CNY | 22.89% |
| 2024 Q1 | 117.02 Million CNY | -3.0% |
| 2023 Q3 | 126.06 Million CNY | 13.58% |
| 2023 Q4 | 120.63 Million CNY | -4.31% |
| 2023 Q2 | 110.99 Million CNY | 26.48% |
| 2023 Q1 | 87.76 Million CNY | -45.21% |
| 2023 FY | 445.46 Million CNY | 2.78% |
| 2022 Q4 | 160.18 Million CNY | 56.89% |
| 2022 FY | 433.42 Million CNY | 23.44% |
| 2022 Q3 | 102.09 Million CNY | 6.79% |
| 2022 Q2 | 95.6 Million CNY | 26.56% |
| 2022 Q1 | 75.54 Million CNY | -25.35% |
| 2021 Q3 | 86.79 Million CNY | 2.99% |
| 2021 Q2 | 84.27 Million CNY | 6.91% |
| 2021 Q4 | 101.2 Million CNY | 16.59% |
| 2021 Q1 | 78.82 Million CNY | -9.6% |
| 2021 FY | 351.1 Million CNY | 8.55% |
| 2020 Q3 | 85.29 Million CNY | -10.44% |
| 2020 Q1 | 55.72 Million CNY | -30.66% |
| 2020 Q2 | 95.23 Million CNY | 70.91% |
| 2020 FY | 323.46 Million CNY | 3.82% |
| 2020 Q4 | 87.2 Million CNY | 2.24% |
| 2019 Q4 | 80.36 Million CNY | -4.4% |
| 2019 FY | 311.54 Million CNY | 8.89% |
| 2019 Q3 | 84.06 Million CNY | 3.76% |
| 2019 Q2 | 81.01 Million CNY | 22.54% |
| 2019 Q1 | 66.1 Million CNY | -23.73% |
| 2018 FY | 286.1 Million CNY | 25.18% |
| 2018 Q4 | 86.67 Million CNY | 0.0% |
| 2017 FY | 228.55 Million CNY | 20.42% |
| 2016 FY | 189.8 Million CNY | 4.77% |
| 2015 FY | 181.15 Million CNY | -2.88% |
| 2014 FY | 186.52 Million CNY | -6.76% |
| 2013 FY | 200.05 Million CNY | 0.0% |